Page last updated: 2024-11-07

sch 42495

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID131965
SCHEMBL ID489493
MeSH IDM0188510

Synonyms (14)

Synonym
sch 42495
ethyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(2-methylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate
unii-5m0j9x6yey
136511-43-8
sch-42495
n-(2(s)-(acetylthiomethyl)-3-(2-methylphenyl)-1-oxopropyl)-l-methionine ethyl ester
5m0j9x6yey ,
SCHEMBL489493
l-methionine,n-[(2s)-2-[(acetylthio)methyl]-3-(2-methylphenyl)-1-oxopropyl]-, ethyl ester
l-methionine, n-((2s)-2-((acetylthio)methyl)-3-(2-methylphenyl)-1-oxopropyl)-, ethyl ester
HY-101682
CS-0021793
l-methionine,n-[(2s)-2-[(acetylthio)methyl]-3-(2-methylphenyl)-1-oxopropyl]-,ethyl ester
AKOS040736347

Research Excerpts

Effects

ExcerptReferenceRelevance
"SCH 42495 has potent antihypertensive effect associated with an enhancement of endogenous hANP and may be clinically useful as a new class of antihypertensive drug."( Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension.
Masuo, K; Mikami, H; Nagano, M; Ogihara, T; Rakugi, H; Yu, H, 1994
)
1.25

Treatment

Treatment with SCH 42495 caused a significant reduction in pulmonary vascular remodelling (25.0%) and right ventricular hypertrophy (0.09%) in CHT20 rats compared with CHV20 controls.

ExcerptReferenceRelevance
"Treatment with SCH 42495 caused a significant reduction in pulmonary vascular remodelling (25.0 +/- 0.01%) and right ventricular hypertrophy (0.52 +/- 0.09) in CHT20 rats compared with CHV20 controls (33.0 +/- 0.02% and 0.61 +/- 0.09 respectively)."( Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia.
Morice, AH; Sheedy, W; Thompson, JS, 1994
)
0.63
"4. Treatment with SCH 42495 caused a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy in hypoxic rats after 10 days."( Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats.
Morice, AH; Sheedy, W; Thompson, JS, 1994
)
0.87

Dosage Studied

ExcerptRelevanceReference
"001) for the duration of the dosing period."( Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.
Crozier, IG; Espiner, EA; Frampton, C; Ikram, H; Kosoglou, T; Nicholls, MG; Rallings, M; Richards, AM; Yandle, TG, 1993
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (77.78)18.2507
2000's4 (22.22)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.97 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (27.78%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]